Turning innovation into patents? It can be an uphill battle. Check out these five effective strategies to improve your odds ...
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...
BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion ...
President Donald Trump’s health secretary nominee last week indicated he’d consider authorizing the government to seize the ...
The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...
Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...
AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...
I liked reading the always-excellent Rob Greenspoon's post about five (almost) instant fixes to the patent system. The next U ...
Unfortunately, failing to implement the necessary IP protections can leave a company vulnerable to copycat competitors that can reduce its valuation and weaken its brand.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback